Good News for ITP Patients: Ianalumab + Eltrombopag Prolongs Time to Treatment Failure VS Eltrombopag Alone
Roger Schutgens, Professor of Thrombosis and Haemostasis at UMC Utrecht, shared on LinkedIn:
“Good news for patients with ITP.
Recently, the results of the VAYHIT2 trial have been published in The New England Journal of Medicine, showing that a course of B-cell–targeted therapy (ianalumab) combined with eltrombopag significantly prolongs time to treatment failure compared to eltrombopag alone in adults with immune thrombocytopenia after first-line steroids (13 months versus 4.7 months).
More patients were able to taper and discontinue eltrombopag (62% versus 39%), supporting the concept of early, disease-modifying treatment in ITP.
It was a joyfull ride to be part of this endeavor.”
Title: Ianalumab plus Eltrombopag in Immune Thrombocytopenia
Authors: Adam Cuker, Thomas Stauch, Nichola Cooper et al.
Read the full article.
Hemostasis Today has more posts you may find interesting.
-
Feb 19, 2026, 16:01Honoring Black Pioneers in Hematology During Black History Month – ASH
-
Feb 19, 2026, 15:16Irina Pahlevanyan: Global Leaders on Courage, Trust, and the True Purpose of Fundraising
-
Feb 19, 2026, 15:12Stéphanie Forté: Transition Readiness in Youth With Sickle Cell Disease
-
Feb 19, 2026, 15:08Tagreed Alkaltham: Strengthening Blood Inventory Governance Through RFID Technology
-
Feb 19, 2026, 14:59Başak Taburoğlu Yılmaz: Improving Diagnosis and Care for Women With Bleeding Disorders
-
Feb 19, 2026, 14:59Munira Borhany: Moving Beyond Stereotypes in the Diagnosis of Bleeding Disorders
-
Feb 19, 2026, 14:56Flora Peyvandi: Personalized VWF Dosing Revolutionizes Surgery in VWD
-
Feb 19, 2026, 14:54Michela Mazzon: The Molecular Trigger Behind the COVID19 Vaccines-Associated ITT
-
Feb 19, 2026, 14:42Luca Palombi: Real-Time Assessment of Venous Hemodynamics During Movement With DUS